Sarepta Therapeutics (NASDAQ:SRPT) Receives Sell (D-) Rating from Weiss Ratings

Key Points

• Sarepta Therapeutics has been given a "sell (D-)" rating by Weiss Ratings, indicating a negative outlook from analysts.
• Despite recent downgrades, eight investment analysts maintain a "buy" rating for Sarepta Therapeutics, suggesting a potential for 179% upside.
• The company's stock recently traded down to $21.61, reflecting a 1.6% decline amid significant trading volume changes.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report)'s stock had its "sell (d-)" rating restated by equities researchers at Weiss Ratings in a report issued on Tuesday,Weiss Ratings reports.

SRPT has been the topic of several other research reports. Jefferies Financial Group dropped their price target on shares of Sarepta Therapeutics from $40.00 to $35.00 and set a "buy" rating on the stock in a research report on Thursday, July 24th. William Blair reiterated an "outperform" rating on shares of Sarepta Therapeutics in a research note on Tuesday, July 29th. JPMorgan Chase & Co. upgraded shares of Sarepta Therapeutics from an "underweight" rating to a "neutral" rating and set a $24.00 target price for the company in a research note on Tuesday, July 29th. BMO Capital Markets raised shares of Sarepta Therapeutics from a "market perform" rating to an "outperform" rating and set a $50.00 target price on the stock in a research report on Monday, September 22nd. Finally, Leerink Partnrs cut shares of Sarepta Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Friday, July 18th. Eight investment analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and seven have given a Sell rating to the stock. According to MarketBeat.com, Sarepta Therapeutics currently has an average rating of "Hold" and an average price target of $34.42.

Sarepta Therapeutics Stock Down 1.6%

Shares of NASDAQ SRPT traded down $0.35 during midday trading on Tuesday, hitting $21.61. 2,614,960 shares of the stock traded hands, compared to its average volume of 6,338,278. The company has a market cap of $2.11 billion, a PE ratio of -24.85 and a beta of 0.51. Sarepta Therapeutics has a one year low of $10.41 and a one year high of $138.81. The business has a 50 day moving average price of $19.21 and a two-hundred day moving average price of $30.10. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.81 and a current ratio of 2.89.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The biotechnology company reported $2.02 EPS for the quarter, beating the consensus estimate of $0.89 by $1.13. Sarepta Therapeutics had a negative return on equity of 1.03% and a negative net margin of 2.34%.The firm had revenue of $611.09 million during the quarter, compared to the consensus estimate of $530.66 million. During the same quarter in the previous year, the company posted $0.07 earnings per share. The company's quarterly revenue was up 68.4% on a year-over-year basis. On average, equities analysts predict that Sarepta Therapeutics will post 2.67 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of SRPT. Federated Hermes Inc. lifted its stake in Sarepta Therapeutics by 347.8% in the 2nd quarter. Federated Hermes Inc. now owns 1,308,199 shares of the biotechnology company's stock worth $22,370,000 after purchasing an additional 1,016,069 shares in the last quarter. Norges Bank purchased a new stake in Sarepta Therapeutics in the 2nd quarter worth approximately $15,619,000. Y Intercept Hong Kong Ltd boosted its stake in Sarepta Therapeutics by 1,736.5% during the second quarter. Y Intercept Hong Kong Ltd now owns 870,181 shares of the biotechnology company's stock valued at $14,880,000 after buying an additional 822,799 shares during the period. Aberdeen Group plc boosted its stake in Sarepta Therapeutics by 91.1% during the second quarter. Aberdeen Group plc now owns 1,242,404 shares of the biotechnology company's stock valued at $21,500,000 after buying an additional 592,125 shares during the period. Finally, Wellington Management Group LLP boosted its stake in Sarepta Therapeutics by 27.9% during the first quarter. Wellington Management Group LLP now owns 2,646,619 shares of the biotechnology company's stock valued at $168,907,000 after buying an additional 577,848 shares during the period. 86.68% of the stock is owned by institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.